Over Nanomi: Nanomi ontwikkelt Nano en Microdeeltjes voor de farmaceutische industrie door middel van onze microfluidic Monosphere Technology. Wij zijn het “center of excellence for complex injectables” van Lupin ltd, een internationaal Indiaas farmaceutisch concern. Nanomi is een internationale, hightech omgeving met een leuke, informele werksfeer. Company Profile: Nanomi, based in Oldenzaal, is a drug delivery company developing pharmaceutical products based on nano- and microparticles. These particles are developed by using Nanomi’s microfluidic Monosphere Technology, enabling the manufacturing of very unique and uniform custom-made particles for a broad range of pharmaceutical products. In 2014 Nanomi was acquired by Lupin and became its center of excellence for complex injectables. Nanomi offers a highly innovative as well as dynamic environment and benefits from its parent company that was founded in 1968. Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BUSINESS INSIGHTS

CORVAL™ LAUNCHES NEW BIOPHARMA COMMERCIALIZATION PLANNING PLATFORM

Corval | September 22, 2021

news image

Corval LLC announced the launch of its cloud-based commercialization planning platform designed for early- to mid-stage biopharma companies. Created by industry veterans with deep experience in biopharma commercialization, the platform provides a technology-based approach that expedites the commercialization planning process and helps teams align on strategic decisions, timing, and future resourcing needs. I have spent my entire career in this space and been exposed ...

Read More

BUSINESS INSIGHTS

PNEUMA SYSTEMS COLLABORATES WITH WEST PHARMACEUTICAL SERVICES, INC. TO IMPROVE THE PATIENT EXPERIENCE

Pneuma Systems Corporation | April 08, 2022

news image

Medical technology company, Pneuma Systems Corporation, has entered a multi-faceted business collaboration with West Pharmaceutical Services, Inc. with the goal of improving the patient's experience with drug therapy. West is a leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable medicines. Pneuma Systems Corporation has developed a family of fluid flow technologies that a...

Read More

PHARMACY MARKET

IAMA THERAPEUTICS ANNOUNCES INITIATION OF PRECLINICAL DEVELOPMENT STUDIES IN DRUG-RESISTANT EPILEPSY UNDER A SERVICE AGREEMENT WITH PSYCHOGENICS

IAMA Therapeutics | July 26, 2022

news image

IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in the lives of individuals suffering from brain disorders, and PsychoGenics Inc., a leader in AI-enabled phenotypic drug discovery and preclinical CRO services, today announced that the companies have entered into a service agreement to identify the efficacy of novel drug candidates in drug-resistant epilepsy. Under the...

Read More

TAKEDA, DEBT IN MIND, OFFLOADS 18 DRUGS IN ASIA PACIFIC TO CELLTRION FOR $278M

Fiercepharma | June 11, 2020

news image

Takeda has earmarked another chunk of business for divestment to help it pay down debt. The Japanese pharma is offloading 18 over-the-counter and prescription drugs marketed in the Asia-Pacific region to South Korea’s Celltrion for $278 million, it said on Thursday. The portfolio generated sales of about $140 million in the fiscal year ended in March 2019, mainly driven by DPP-4 diabetes drug Nesina and hypertension med Edarbi, Takeda said. It will continue to manufacture the products and ...

Read More
news image

BUSINESS INSIGHTS

CORVAL™ LAUNCHES NEW BIOPHARMA COMMERCIALIZATION PLANNING PLATFORM

Corval | September 22, 2021

Corval LLC announced the launch of its cloud-based commercialization planning platform designed for early- to mid-stage biopharma companies. Created by industry veterans with deep experience in biopharma commercialization, the platform provides a technology-based approach that expedites the commercialization planning process and helps teams align on strategic decisions, timing, and future resourcing needs. I have spent my entire career in this space and been exposed ...

Read More
news image

BUSINESS INSIGHTS

PNEUMA SYSTEMS COLLABORATES WITH WEST PHARMACEUTICAL SERVICES, INC. TO IMPROVE THE PATIENT EXPERIENCE

Pneuma Systems Corporation | April 08, 2022

Medical technology company, Pneuma Systems Corporation, has entered a multi-faceted business collaboration with West Pharmaceutical Services, Inc. with the goal of improving the patient's experience with drug therapy. West is a leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable medicines. Pneuma Systems Corporation has developed a family of fluid flow technologies that a...

Read More
news image

PHARMACY MARKET

IAMA THERAPEUTICS ANNOUNCES INITIATION OF PRECLINICAL DEVELOPMENT STUDIES IN DRUG-RESISTANT EPILEPSY UNDER A SERVICE AGREEMENT WITH PSYCHOGENICS

IAMA Therapeutics | July 26, 2022

IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in the lives of individuals suffering from brain disorders, and PsychoGenics Inc., a leader in AI-enabled phenotypic drug discovery and preclinical CRO services, today announced that the companies have entered into a service agreement to identify the efficacy of novel drug candidates in drug-resistant epilepsy. Under the...

Read More
news image

TAKEDA, DEBT IN MIND, OFFLOADS 18 DRUGS IN ASIA PACIFIC TO CELLTRION FOR $278M

Fiercepharma | June 11, 2020

Takeda has earmarked another chunk of business for divestment to help it pay down debt. The Japanese pharma is offloading 18 over-the-counter and prescription drugs marketed in the Asia-Pacific region to South Korea’s Celltrion for $278 million, it said on Thursday. The portfolio generated sales of about $140 million in the fiscal year ended in March 2019, mainly driven by DPP-4 diabetes drug Nesina and hypertension med Edarbi, Takeda said. It will continue to manufacture the products and ...

Read More